Cellectar BioSciences Unveils Pipeline Advancements in Phospholipid Drug Conjugate Oncology Therapies
I'm PortAI, I can summarize articles.
Cellectar BioSciences Inc. announced advancements in its phospholipid drug conjugate platform, focusing on targeted radiotherapeutics for oncology. The company is ready for a Phase 1b/2a study for triple negative breast cancer and finalizing an IND application for CLR 225 in solid tumors. It aims for conditional market authorization in Europe and accelerated approval in the U.S. for iopofosine I 131. Cellectar plans further development and commercialization partnerships in the U.S. and EU.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments